Stockscreener 앱 받기
7.67
0.52%
-0.04
전일 마감가:
$7.71
열려 있는:
$7.71
하루 거래량:
163.89K
Relative Volume:
0.82
시가총액:
$413.29M
수익:
-
순이익/손실:
$-35.10M
주가수익비율:
-10.88
EPS:
-0.7051
순현금흐름:
$-31.49M
1주 성능:
+0.66%
1개월 성능:
+43.90%
6개월 성능:
-6.00%
1년 성능:
+108.99%
1일 변동 폭
$7.31
$7.98
1주일 범위
$7.31
$8.525
52주 변동 폭
$3.575
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
명칭
Diamedica Therapeutics Inc
전화
(763) 496-5454
주소
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
7.67 | 413.29M | 0 | -35.10M | -31.49M | -0.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-14 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-30 | 개시 | TD Cowen | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-06-22 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 개시 | Oppenheimer | Outperform |
| 2021-02-17 | 개시 | ROTH Capital | Buy |
| 2020-10-30 | 개시 | Guggenheim | Buy |
| 2020-07-08 | 개시 | Maxim Group | Buy |
| 2019-04-30 | 개시 | Dougherty & Company | Buy |
| 2019-03-05 | 개시 | Lake Street | Buy |
모두보기
Diamedica Therapeutics Inc 주식(DMAC)의 최신 뉴스
DMAC PE Ratio & Valuation, Is DMAC Overvalued - Intellectia AI
Enterprise value to EBITDA forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
Price to sales forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
DMAC Q1 2026 Earnings: EPS Misses Estimates as Clinical Pipeline AdvancesEarnings Growth Forecast - dars.gov.et
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DiaMedica Therapeutics Inc. Actuals & Estimates (NASDAQ:DMAC) - TradingView
DMAC Forecast — Price Target — Prediction for 2027 - TradingView
DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
DiaMedica Therapeutics Up 10%, Insider Buyers Are Up 43% - simplywall.st
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - BioSpace
DiaMedica Therapeutics (DMAC) Initiates Phase 2 Trial for DM199 in Fetal Growth Restriction - GuruFocus
DiaMedica doses first patients in fetal growth restriction trial - Investing.com
DiaMedica Therapeutics Inc (DMAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating - Moomoo
DiaMedica Therapeutics Inc (DMAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
DiaMedica Therapeutics Inc (DMAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DiaMedica Therapeutics Inc (DMAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
DiaMedica Therapeutics Inc (DMAC) Valuation: PE, PB & Fair Value Analysis - TradingKey
DiaMedica Therapeutics Inc (DMAC) Institutional Confidence - TradingKey
DiaMedica Therapeutics Inc - TradingKey
DiaMedica Therapeutics Inc (DMAC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DiaMedica Therapeutics receives written response from FDA on DM199 - TipRanks
DiaMedica Therapeutics (DMAC) Updates on FDA Response for DM199 Development - GuruFocus
DiaMedica to conduct rat study addressing FDA data request - Investing.com
DiaMedica to conduct rat study addressing FDA data request By Investing.com - Investing.com Canada
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program - Business Wire
DiaMedica Therapeutics (DMAC) Hovers Near Key Support After Slight PullbackGrowth Stock Picks - newsline.com
DMAC Q1 2026 Earnings: Clinical Progress Drives Optimism Despite Slight EPS MissEarnings Miss Streak - newsline.com
DiaMedica Therapeutics (DMAC) Gains 3.66% as Biotech Stock Tests Key Resistance ZonePut Spread Alert - newsline.com
DiaMedica Therapeutics (DMAC) director granted 40,412 stock options at $5.84 - Stock Titan
DiaMedica (DMAC) director Richard Kuntz receives grant of 40,412 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) director granted 40,412-share stock option award - Stock Titan
DiaMedica (DMAC) director Tanya Lewis awarded 40,412 stock options at $5.84 - Stock Titan
DiaMedica Therapeutics (DMAC) director receives 40,412-share stock option grant - Stock Titan
DiaMedica Therapeutics (NASDAQ: DMAC) director receives grant of 51,189 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) CEO awarded 380,000 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) CFO awarded 162,000 stock options at $5.84 strike - Stock Titan
DiaMedica Therapeutics (DMAC) CMO receives 67,500 stock options expiring 2036 - Stock Titan
DiaMedica Shares Down Ahead of Stroke Trial Update - Bez Kabli
DiaMedica (DMAC) Q4 2025 Earnings Transcript - The Globe and Mail
DMACDiaMedica Therapeutics Inc Latest SEC Filings - Finviz
DiaMedica Therapeutics (DMAC) Slides 2.76% as Biotech Sector Headwinds Pressure Small-Cap NamesWave Equality - The Legal Advocate
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 - BioSpace
DMAC Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline AdvancesProfit Guidance Range - The Legal Advocate
DiaMedica Therapeutics (DMAC) Gains 4% as Stock Approaches Key Resistance LevelCumulative Volume - The Legal Advocate
DiaMedica Therapeutics (DMAC) Gains 2.43% as Buyers Defend Key SupportSynthetic Long - The Legal Advocate
DiaMedica Shareholders Approve Governance, Compensation and Incentive Plan - The Globe and Mail
DMAC Q1 2026 Earnings: Wider Loss Than Expected as Clinical Pipeline AdvancesFinancial Health Score - thelegaladvocate.com
DiaMedica Therapeutics (NASDAQ: DMAC) investors approve directors, pay and 3.5M-share incentive plan boost - Stock Titan
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - BioSpace
Diamedica Therapeutics Inc (DMAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Diamedica Therapeutics Inc 주식 (DMAC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Nov 21 '25 |
Buy |
7.41 |
208,872 |
1,547,574 |
8,712,390 |
| STAHLBERG JAN | 10% Owner |
Nov 18 '25 |
Buy |
6.75 |
182,882 |
1,234,618 |
8,134,740 |
| STAHLBERG JAN | 10% Owner |
Nov 17 '25 |
Buy |
6.52 |
187,393 |
1,221,165 |
7,951,858 |
| STAHLBERG JAN | 10% Owner |
Nov 20 '25 |
Buy |
7.41 |
128,426 |
951,213 |
8,503,518 |
| STAHLBERG JAN | 10% Owner |
Nov 25 '25 |
Buy |
8.57 |
73,099 |
626,817 |
8,825,742 |
| STAHLBERG JAN | 10% Owner |
Nov 24 '25 |
Buy |
7.89 |
40,253 |
317,721 |
8,752,643 |
| Parsons James T. | Director |
Nov 21 '25 |
Option Exercise |
2.20 |
12,000 |
26,400 |
87,854 |
| STAHLBERG JAN | 10% Owner |
Aug 25 '25 |
Buy |
6.00 |
338,265 |
2,029,252 |
7,654,045 |
| STAHLBERG JAN | 10% Owner |
Aug 13 '25 |
Buy |
5.91 |
293,601 |
1,734,918 |
7,058,066 |
| STAHLBERG JAN | 10% Owner |
Aug 14 '25 |
Buy |
5.99 |
70,414 |
421,921 |
7,128,480 |
2.64%
자본화:
|
볼륨(24시간):